<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Inst of Infections and Immunity</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/12A06C0C-6FAE-445B-A949-C053C0736A7D"><gtr:id>12A06C0C-6FAE-445B-A949-C053C0736A7D</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Pleass</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300145"><gtr:id>442D97F7-393E-4D83-9335-0D56F026D679</gtr:id><gtr:title>The generation and analysis of function of novel antibodies for the treatment of malaria</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300145</gtr:grantReference><gtr:abstractText>Malaria kills approximately 5 children every minute and poses an increasing risk to travellers. Although debt, civil war, and poor government are partially responsible for the resurgence of malaria, the emergence of drug resistant parasites and insecticide resistant mosquitoes are also to blame. New methods of combating this blood borne parasite are therefore required. One promising method is to use antibodies. Antibodies are flexible molecules found in blood and are produced during a natural malaria infection and in response to vaccination. They bind and neutralize malaria parasites and prepare them for uptake and destruction by killer cells, which are also found in blood. However, the parasite can evade killing by constantly changing the molecules on its surface that are seen by antibodies, a process known as antigenic variation. Modern technologies now enable us to identify regions on the surface of the parasite that don?t change or change very slowly. Human antibodies that see these regions can then be made artificially in the test-tube and tested for their effectiveness at killing parasites. We have shown that one particular type of antibody, termed IgA, is very effective at recruiting killer cells to kill malaria parasites outside of the human body. We will test if this is also true in humans suffering from malaria. Through fieldwork with collaborators in Africa we hope one day to test the effectiveness of these antibodies at curbing malaria in trials with human volunteers.</gtr:abstractText><gtr:technicalSummary>There are approximately 500 million clinical cases of malaria each year, resulting in approximately 3 million deaths. The most dangerous form of the disease is caused by Plasmodium falciparum. The available antimalarials have toxic side effects and the parasite has developed resistance to cheap and previously reliable drugs like chloroquine and few new drugs are in development. Although a vaccine against malaria is considered the ultimate goal, its development has been beset with difficulties and the search for alternative therapies to treat malaria has become of major importance. As a novel approach, I propose to generate recombinant human antibody reagents designed both to remove merozoites from the circulation and protect an individual from re-infection. These reagents are designed to recognize invariant epitopes on the malaria parasite and link them to triggering molecules on phagocytes, particularly Fc-receptors (FcR), thereby harnessing optimally their phagocytic capacity. Human recombinant IgG, IgA, and diabodies targeting either P.falciparum or P.yeolii merozoites, will be generated by cloning antibody variable (V) domains against Plasmodium antigens from hybridomas or from antibody repertoire phage display libraries, generated by the MRC collaborative centre from immune Gambian adults, and linking them to constant or V domains recognizing FcR in suitable expression vectors. The killing ability of these reagents will be tested on malaria parasites in vitro (P.falciparum and P.yoelii) and in vivo with P.yoelii (in mice transgenic for human FcgR and FcaR). These reagents, in addition to their potential therapeutic capacity, will enable us to elucidate more precisely the role FcRs play in immunity to malaria. Work done as part of a Wellcome Trust Training Fellowship has hinted that human serum IgA1 may be very effective at eliminating malaria parasites in vitro, and I plan to investigate if this class of antibody has a protective role in vivo, in patients suffering from malaria. Reagents such as those detailed here now offer colleagues at NIMR an indefinite supply of reproducible standards for both structural studies, and neutralization assays aimed at obtaining in vitro correlates of protection in the development of optimal vaccines.</gtr:technicalSummary><gtr:fund><gtr:end>2009-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>438987</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited Talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A744BFDB-2108-4BA5-9CD0-7EDCE549BAEA</gtr:id><gtr:impact>I have spoken about my work at numerous scientific congresses and been invited by numerous external malaria groups globally to talks. For example, I recently spoke about this MRC funded work at EMBL Heidelberg and Copenhagen in 2008

These have resulted in significant new collaborations e.g. with Professor Lars Hviid and ideas for grants. It has also resulted in an invitation to a future prestigious Gordon Research Conference</gtr:impact><gtr:outcomeId>CF9DC258C19</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper Articles</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C618249-4CE7-4BD0-A5C5-5973CD6617F4</gtr:id><gtr:impact>My work funded by the MRC has been written about in numerous newspaper articles in The Times, The Daily Mail, La Monde, The Daily Telegraph, New Scientist etc. I have also written about Malaria in a letter published by the Times.

More staff</gtr:impact><gtr:outcomeId>5A5C78977A0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.dailymail.co.uk/sciencetech/article-457039/British-teams-malaria-breakthrough.html</gtr:url><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ACAA8F02-0661-4A37-9A7C-05F323EEB0C0</gtr:id><gtr:impact>I was interviewed by Radio Smooth and my postdoc by Earthsky radio http://www.earthsky.org/radioshows/51675/malaria-vaccine-research-aided-by-tests-on-mice

None that I'm aware of</gtr:impact><gtr:outcomeId>166127B415B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CE81B3FB-B51F-4531-8D85-992BD073D9FA</gtr:id><gtr:impact>I was interviewed by More 4 news and the highlight of this interview can be seen at http://www.channel4.com/news/articles/society/health/scientists+discover+malaria+vaccine/526547

Asked to write more articles</gtr:impact><gtr:outcomeId>71100642280</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.channel4.com/news/articles/society/health/scientists+discover+malaria+vaccine/526547</gtr:url><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Halley Stewart Trust, Project</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>Sir Halley Stewart Trust</gtr:fundingOrg><gtr:id>3EE59B88-C6D3-4656-BD5F-D5F8B45B2E17</gtr:id><gtr:outcomeId>BD1965F9C780</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55777</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Theo Murphy Blue Skies Award</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>CDBE5358-94AB-4678-A81D-375496F71240</gtr:id><gtr:outcomeId>BUVoDzerqzJ0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New in vivo model to test the efficacy of human antibodies at protecting against malaria</gtr:description><gtr:id>494A27B5-4B7E-4BAB-9672-4518DB659112</gtr:id><gtr:impact>Reviews and papers and marked understanding of vaccine development</gtr:impact><gtr:outcomeId>F03449FE0D2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Double Transgenic Model</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E3998F01-2848-43D3-8838-5255AF6EE0AE</gtr:id><gtr:title>IgM, Fc mu Rs, and malarial immune evasion.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be463e4a2b8585bf6dcdae1c2ce8816a"><gtr:id>be463e4a2b8585bf6dcdae1c2ce8816a</gtr:id><gtr:otherNames>Czajkowsky DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>Y8Zy6woE2wR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2CABD1C-7319-4345-9205-F10E844E8BE8</gtr:id><gtr:title>Reply to &amp;quot;chloroquine, an antifungal but also a fertility drug&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4209d840086f6e35553e2692b597fb8"><gtr:id>a4209d840086f6e35553e2692b597fb8</gtr:id><gtr:otherNames>Islahudin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>54576caf6f0c54.97519724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF4E43A0-4B48-44DB-B8C5-E8BBA396430A</gtr:id><gtr:title>The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19).</gtr:title><gtr:parentPublicationTitle>BMC biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1472-6750</gtr:issn><gtr:outcomeId>pm_15338_28_21781305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB8E4E2E-E772-4690-AA43-63998D7ABCAB</gtr:id><gtr:title>A novel human IgA monoclonal antibody protects against tuberculosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ede5f802f9fa4537121db24cb546638d"><gtr:id>ede5f802f9fa4537121db24cb546638d</gtr:id><gtr:otherNames>Balu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15338_28_21257971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F9B8BB1-6068-4C86-82DE-64DC9B1AFE47</gtr:id><gtr:title>Cloning and characterization of an immunoglobulin A Fc receptor from cattle.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83e5a0d9d64cff30f186afd5523e059c"><gtr:id>83e5a0d9d64cff30f186afd5523e059c</gtr:id><gtr:otherNames>Morton HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>5898B180284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1A33F5B-37F5-45E2-B2BB-35BDE3A064FE</gtr:id><gtr:title>Fc-receptors and immunity to malaria: from models to vaccines.</gtr:title><gtr:parentPublicationTitle>Parasite immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41ad23200a029cf46f495b74e21df3c2"><gtr:id>41ad23200a029cf46f495b74e21df3c2</gtr:id><gtr:otherNames>Pleass RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0141-9838</gtr:issn><gtr:outcomeId>0482D612_00482D612_0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACDCBDFB-B612-45EC-B7F0-163093A9BBEB</gtr:id><gtr:title>Cell wall perturbation sensitizes fungi to the antimalarial drug chloroquine.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4209d840086f6e35553e2692b597fb8"><gtr:id>a4209d840086f6e35553e2692b597fb8</gtr:id><gtr:otherNames>Islahudin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>54576d2e5f9ff8.61014242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDED2277-2EE2-4878-AA9D-2D0F7763C53C</gtr:id><gtr:title>The antimalarial drug quinine interferes with serotonin biosynthesis and action.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4209d840086f6e35553e2692b597fb8"><gtr:id>a4209d840086f6e35553e2692b597fb8</gtr:id><gtr:otherNames>Islahudin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>545764a45327c2.50966653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEF5C724-9230-4825-AC53-1001148833C9</gtr:id><gtr:title>Quinine interactions with tryptophan and tyrosine in malaria patients, and implications for quinine responses in the clinical setting.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4209d840086f6e35553e2692b597fb8"><gtr:id>a4209d840086f6e35553e2692b597fb8</gtr:id><gtr:otherNames>Islahudin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_15338_28_22763566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DD961BE-96C5-4500-A4B2-FA100238A59D</gtr:id><gtr:title>Structural requirements for the interaction of human IgA with the human polymeric Ig receptor.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/523b9de82b125a4cb2fc7697e90cbe50"><gtr:id>523b9de82b125a4cb2fc7697e90cbe50</gtr:id><gtr:otherNames>Lewis MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>A086570797D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4109321B-DE2D-4F6B-B98F-8629C6849F41</gtr:id><gtr:title>T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc38a3c8d7daa55241aa596afb1e2901"><gtr:id>cc38a3c8d7daa55241aa596afb1e2901</gtr:id><gtr:otherNames>Forbes EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15338_28_22984589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EB41344-FF70-498B-8084-51A053A00CA1</gtr:id><gtr:title>Heterogeneous interspecific interactions in a host-parasite system.</gtr:title><gtr:parentPublicationTitle>International journal for parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40604f71036e9ecc7828cfc1afb7af62"><gtr:id>40604f71036e9ecc7828cfc1afb7af62</gtr:id><gtr:otherNames>Jackson JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0020-7519</gtr:issn><gtr:outcomeId>F48F88B8DEE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DE2B2C7-A291-47DB-9649-3D576ACB987D</gtr:id><gtr:title>Identification of residues in the Cmu4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1).</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9297e5255d35e5128f5fee26970ce2b7"><gtr:id>9297e5255d35e5128f5fee26970ce2b7</gtr:id><gtr:otherNames>Ghumra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>A1DF03DD6A2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C6318B4-1A92-45E7-9CF7-EAE8A4556428</gtr:id><gtr:title>Fc-fusion proteins: new developments and future perspectives.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be463e4a2b8585bf6dcdae1c2ce8816a"><gtr:id>be463e4a2b8585bf6dcdae1c2ce8816a</gtr:id><gtr:otherNames>Czajkowsky DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>pm_15338_28_22837174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62A0CF92-DFC7-4296-9FF0-D6354F3268F4</gtr:id><gtr:title>Acanthamoeba interactions with the blood-brain barrier under dynamic fluid flow.</gtr:title><gtr:parentPublicationTitle>Experimental parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/543ef7c62fde390a37c0f6afdaf8ad0d"><gtr:id>543ef7c62fde390a37c0f6afdaf8ad0d</gtr:id><gtr:otherNames>Edwards-Smallbone J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-4894</gtr:issn><gtr:outcomeId>pm_15338_28_22960347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6174D5D-F00E-4634-9A90-7D25F4C3EDFE</gtr:id><gtr:title>Characterization of immunoglobulin binding by schistosomes.</gtr:title><gtr:parentPublicationTitle>Parasite immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d24fdfc9e9f243d120e2a20a9f7b7f8"><gtr:id>4d24fdfc9e9f243d120e2a20a9f7b7f8</gtr:id><gtr:otherNames>McIntosh RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0141-9838</gtr:issn><gtr:outcomeId>2013D09E4D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E0EB724-3879-432D-97F1-49ED1CA04124</gtr:id><gtr:title>Escherichia coli do not express Fc-receptors for human immunoglobulin G (IgG).</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9297e5255d35e5128f5fee26970ce2b7"><gtr:id>9297e5255d35e5128f5fee26970ce2b7</gtr:id><gtr:otherNames>Ghumra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>D9E6B2BDB39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D9A9608-E341-40CC-89D1-A7338E44E8D5</gtr:id><gtr:title>Inhibition of erythrocyte invasion and Plasmodium falciparum merozoite surface protein 1 processing by human immunoglobulin G1 (IgG1) and IgG3 antibodies.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c492a550d996afcbcf9ab08f192bf17"><gtr:id>8c492a550d996afcbcf9ab08f192bf17</gtr:id><gtr:otherNames>Lazarou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>36C20E0110A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>547DA038-096A-464A-8680-2DB87FFC4DF7</gtr:id><gtr:title>Glycoproteomic characterization of recombinant mouse a-dystroglycan.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d2b9ffc72371ff3aac01acd79f7be7f"><gtr:id>0d2b9ffc72371ff3aac01acd79f7be7f</gtr:id><gtr:otherNames>Harrison R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>pm_15338_28_22241827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDCCD9C2-549C-4F7A-9296-4F822913DE11</gtr:id><gtr:title>Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d0e3a7e251ddfd1290bf38f51937a3"><gtr:id>31d0e3a7e251ddfd1290bf38f51937a3</gtr:id><gtr:otherNames>Aslam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>C923B9706E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08F3BE52-3D51-4279-BAF7-788CFE25E7F2</gtr:id><gtr:title>Bifunctional nanotube scaffolds for diverse ligands are purified simply from Escherichia coli strains coexpressing two functionalized flagellar genes.</gtr:title><gtr:parentPublicationTitle>Nano letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5aa57b170acd8fd1f8ccce4111541a4c"><gtr:id>5aa57b170acd8fd1f8ccce4111541a4c</gtr:id><gtr:otherNames>Woods RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1530-6984</gtr:issn><gtr:outcomeId>84A12531B4E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF71633B-8900-4BA5-BB76-B638AD2BEA8E</gtr:id><gtr:title>Piggybacking schistosome invasion: similarities are only skin deep.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41ad23200a029cf46f495b74e21df3c2"><gtr:id>41ad23200a029cf46f495b74e21df3c2</gtr:id><gtr:otherNames>Pleass RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>C869E7A73C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4DD7CBA-9AB5-4D6F-BB9C-79B89585B383</gtr:id><gtr:title>Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba120ad0efef8b4c8420f4874b56f752"><gtr:id>ba120ad0efef8b4c8420f4874b56f752</gtr:id><gtr:otherNames>Llewellyn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>54576bc3905624.32840826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49624B4B-8892-4114-9A50-6209C64DA62F</gtr:id><gtr:title>The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_15338_28_23609325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5131D040-40D1-4B3E-80BB-FD834A5FB4AE</gtr:id><gtr:title>Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9297e5255d35e5128f5fee26970ce2b7"><gtr:id>9297e5255d35e5128f5fee26970ce2b7</gtr:id><gtr:otherNames>Ghumra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>A55D72FF3A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20F00259-858B-4D4E-B7D2-435801290F07</gtr:id><gtr:title>The importance of human FcgammaRI in mediating protection to malaria.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d24fdfc9e9f243d120e2a20a9f7b7f8"><gtr:id>4d24fdfc9e9f243d120e2a20a9f7b7f8</gtr:id><gtr:otherNames>McIntosh RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>AB9D2813280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DE22558-0901-4B23-AA43-C90CF46B662A</gtr:id><gtr:title>Opinion: antibody-based therapies for malaria.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41ad23200a029cf46f495b74e21df3c2"><gtr:id>41ad23200a029cf46f495b74e21df3c2</gtr:id><gtr:otherNames>Pleass RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>CDE798CF95D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>839A077E-39E4-46E2-A3C4-B78291B93DDF</gtr:id><gtr:title>Cloning and characterization of equine CD89 and identification of the CD89 gene in chimpanzees and rhesus macaques.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83e5a0d9d64cff30f186afd5523e059c"><gtr:id>83e5a0d9d64cff30f186afd5523e059c</gtr:id><gtr:otherNames>Morton HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>CD99F1A4DA1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8BDADF4-2235-4FD7-BFAB-355A5F1766B1</gtr:id><gtr:title>The secretory tailpiece isoform of IgE is not associated with allergy.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d0e3a7e251ddfd1290bf38f51937a3"><gtr:id>31d0e3a7e251ddfd1290bf38f51937a3</gtr:id><gtr:otherNames>Aslam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>E3E91950BF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>005CF5DD-4CA7-4021-A058-AA8C95E2AFFE</gtr:id><gtr:title>IgA is a more potent inducer of NADPH oxidase activation and degranulation in blood eosinophils than IgE.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41ad23200a029cf46f495b74e21df3c2"><gtr:id>41ad23200a029cf46f495b74e21df3c2</gtr:id><gtr:otherNames>Pleass RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>21D7AB9744B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A35204C-F0F4-4D12-A14C-B2F050C66369</gtr:id><gtr:title>Evasion of immunity to Plasmodium falciparum malaria by IgM masking of protective IgG epitopes in infected erythrocyte surface-exposed PfEMP1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18c4f212ef5dd0b0d615c53d9a08492"><gtr:id>f18c4f212ef5dd0b0d615c53d9a08492</gtr:id><gtr:otherNames>Barfod L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_15338_28_21746929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A270F78-7787-407E-AA75-6263A73955C8</gtr:id><gtr:title>When is a malaria immune complex not an immune complex?</gtr:title><gtr:parentPublicationTitle>Parasite immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41ad23200a029cf46f495b74e21df3c2"><gtr:id>41ad23200a029cf46f495b74e21df3c2</gtr:id><gtr:otherNames>Pleass RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0141-9838</gtr:issn><gtr:outcomeId>56a758d3290106.21037502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>334F1C03-2C6F-4317-83FF-6491B380BFB7</gtr:id><gtr:title>The generation and evaluation of two panels of epitope-matched mouse IgG1, IgG2a, IgG2b and IgG3 antibodies specific for Plasmodium falciparum and Plasmodium yoelii merozoite surface protein 1-19 (MSP1(19)).</gtr:title><gtr:parentPublicationTitle>Experimental parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9387744ea0e935d038c1c4ba4a46e314"><gtr:id>9387744ea0e935d038c1c4ba4a46e314</gtr:id><gtr:otherNames>Adame-Gallegos JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-4894</gtr:issn><gtr:outcomeId>pm_15338_28_22343045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BD05535-3B6B-46C5-8018-B065D895D0A9</gtr:id><gtr:title>Antibody- and Fc-receptor-based therapeutics for malaria.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>AA9BFD61180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>784CA801-6A31-4FC9-ACE5-3EFA3CB5A49B</gtr:id><gtr:title>Characterization of the ligand binding site of the bovine IgA Fc receptor (bFc alpha R).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83e5a0d9d64cff30f186afd5523e059c"><gtr:id>83e5a0d9d64cff30f186afd5523e059c</gtr:id><gtr:otherNames>Morton HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>BA33215F0CF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300145</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>